FISCHER Fischer Medical Ventures Q2 FY26 results (Jul–Sep 2025) and concall
Fischer Medical Ventures delivered a strong Q2 and H1 FY26, driven by significant revenue and profitability growth across its Diagnostic and Preventive Healthcare segments. The company reported a 118% YoY revenue increase in Q2 to INR 86 crores and a 25-fold EBITDA growth to INR 19 crores, reflecting strong operating leverage and strategic focus on high-margin solutions. Management highlighted expansion in both domestic and export markets, alongside advancements in MRI and AI-enabled diagnostic technologies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 117.6%, net profit up 4693.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 40 | 12 | 49 | 23 | 86 +118% |
| EBITDA | 1 | 0 | 3 | 4 | 16 +3144% |
| Net profit | 0 | -0 | 1 | 5 | 14 +4693% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
